Published • loading... • Updated
New human data hints at psychedelics' potential to combat inflammation
The open-label trial found lower inflammatory markers after two doses, and researchers said the changes persisted for 30 days.
Summary by Npr
7 Articles
7 Articles
Psilocybin Tied to Lower Inflammation in Parkinson's Trial
(MedPage Today) -- Markers of systemic inflammation and mitochondrial stress were reduced after psilocybin therapy in Parkinson's disease patients with mood dysfunction, a small nonrandomized trial showed. Relative to baseline, an inflammatory...
·New York, United States
Read Full Article
New human data hints at psychedelics' potential to combat inflammation
Lab studies have shown that psychedelics like psilocybin can lower inflammation and may be protective for a range of illnesses. Now, researchers are publishing some of the first data in humans that signals this holds potential for patients with neurodegenerative diseases like Parkinson's disease.
·San Diego, United States
Read Full Article
Psilocybin reduced inflammation markers and mitochondrial stress from Parkinson's disease
Coverage Details
Total News Sources7
Leaning Left2Leaning Right0Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 40%
C 60%
Factuality
To view factuality data please Upgrade to Premium
